Overview
- An international clinical trial found that NOUS-209 induced strong T-cell responses in all evaluable participants.
- Among 45 carriers of Lynch syndrome with precancerous polyps, 85% had no new advanced polyps after one year of follow-up.
- Investigators describe the data as early evidence that vaccination could intercept tumor development in this high-risk group.
- No serious adverse events related to the vaccine were reported, suggesting it was well tolerated in the study.
- The study, led by MD Anderson’s Eduardo Vilar-Sánchez and funded by developer Nouscom, precedes larger controlled trials now in preparation.